Acromegaly: Patient And Physician Perspectives
Acromegaly: Patient And Physician Perspectives
The purpose of the study is to assess the experiences of individuals with acromegaly who are
 receiving injections as part of their treatment regimen. Another objective of the study is to
 compare the patients' perception with their doctors' perceptions. The answers are important
 to help researchers and physicians understand what it is really like to take currently
 available treatments so that they can make efforts to improve patients' healthcare
 experiences, reduce treatment burden and, ultimately, improve patient's quality of life.
Inclusion Criteria:

 -  Age >=18 years-old and <95 years-old

 -  Patient self-reported acromegaly diagnosis which will be further confirmed by a
 knowledge screening based on current medications and doses

 -  Currently on injectable Somatostatin analogues (SSA), Sandostatin® LAR or Somatuline®
 Depot, for >=12 months

 -  Have not had a change in dosage of their acromegaly treatment at the time of or since
 their last office visit

 -  Have seen their treating acromegaly physician within the past 12 +/-2 months NOTE:
 This timeframe allows two additional months for scheduling an appointment with their
 physician, since most patients should see their acromegaly physician at least once
 every 12 months

 -  Ability to read and understand English

 -  Live and receive acromegaly treatments in the US

 -  Willing to provide signed informed consent

 Exclusion Criteria:

 -  Previous or current participant in Mycapssa® (octreotide capsules) trial

 -  Use of Pegvisomant (Somavert®) monotherapy

 -  Use of Pasireotide (Signifor®)